1186

543245

GLAND

img img img img
No Data Available

GLAND PHARMA LIMITED Share Price Update

As of the latest trading session, GLAND PHARMA LIMITED is trading at ₹2250, down by ₹-63.00 or -2.72% from its previous close. The stock has moved between ₹2230.00 and ₹2337.50 today. Over the past year, the stock has delivered a return of 51.38%. In the last month, it has returned 30.27%.

GLAND PHARMA LIMITED performance

Today’s low Today’s high
₹ 2230.00 ₹ 2337.50
₹ 2250.00
52 week low 52 week high
₹ 1513.40 ₹ 2396.00
₹ 2250.00
Open Price ₹ 2315.00
Prev. Close ₹ 2313.00
Volume (Shares) 218609.00
Total traded value ₹ 4918.70
Upper Circuit ₹ 2775.60
Lower Circuit ₹ 1850.40
info

Investment Returns

Over 1 Month 30.27% Over 3 Months 26.93% Over 6 Months 30.38% Over 1 Year 51.38%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

GLAND PHARMA LIMITED fundamentals


  • Market cap (Cr) 37,070.20
  • P/E Ratio (TTM) 29.33
  • Beta 0.75
  • Book Value / share 656.12
  • Return on equity 11.62%
  • EPS (TTM) 79.97
  • Dividend yield 0.86%
  • Net profit/quarter (Cr) 420.45
info icon alternate text
  • Market cap (Cr) 37,066.10
  • P/E Ratio (TTM) 29.33
  • Beta 0.70
  • Book Value / share 656.12
  • Return on equity 11.62%
  • EPS (TTM) 79.97
  • Dividend yield 0.86%
  • Net profit/quarter (Cr) 420.45
info icon alternate text

GLAND PHARMA LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 1261.59
Operating Expense 803.16
Net Profit 420.45
Net Profit Margin (%) 33.32
Earnings Per Share (EPS) 25.52
EBITDA 614.07
Effective Tax Rate (%) 25.55
Particulars DEC 2025 (Values in Cr)
Revenue 1177.51
Operating Expense 800.92
Net Profit 307.85
Net Profit Margin (%) 26.14
Earnings Per Share (EPS) 18.68
EBITDA 457.49
Effective Tax Rate (%) 25.36
Particulars SEP 2025 (Values in Cr)
Revenue 1074.15
Operating Expense 748.07
Net Profit 302.00
Net Profit Margin (%) 28.11
Earnings Per Share (EPS) 18.33
EBITDA 457.48
Effective Tax Rate (%) 26.10
Particulars JUN 2025 (Values in Cr)
Revenue 1038.84
Operating Expense 731.20
Net Profit 269.26
Net Profit Margin (%) 25.91
Earnings Per Share (EPS) 16.34
EBITDA 413.59
Effective Tax Rate (%) 25.69
Particulars MAR 2025 (Values in Cr)
Revenue 1030.35
Operating Expense 682.75
Net Profit 290.00
Net Profit Margin (%) 28.14
Earnings Per Share (EPS) 17.60
EBITDA 437.84
Effective Tax Rate (%) 25.89
Particulars MAR 2026 (Values in Cr)
Revenue 4552.09
Operating Expense 3083.33
Net Profit 1299.55
Net Profit Margin (%) 28.54
Earnings Per Share (EPS) 78.88
EBITDA 1942.62
Effective Tax Rate (%) 25.66
Particulars MAR 2025 (Values in Cr)
Revenue 4116.15
Operating Expense 2865.64
Net Profit 1089.75
Net Profit Margin (%) 26.47
Earnings Per Share (EPS) 66.15
EBITDA 1657.69
Effective Tax Rate (%) 25.64
Particulars MAR 2024 (Values in Cr)
Revenue 4167.43
Operating Expense 2928.59
Net Profit 1043.33
Net Profit Margin (%) 25.03
Earnings Per Share (EPS) 63.35
EBITDA 1575.44
Effective Tax Rate (%) 25.76
Particulars MAR 2023 (Values in Cr)
Revenue 3616.53
Operating Expense 2752.12
Net Profit 775.83
Net Profit Margin (%) 21.45
Earnings Per Share (EPS) 47.12
EBITDA 1202.55
Effective Tax Rate (%) 25.99
Particulars MAR 2022 (Values in Cr)
Revenue 4400.71
Operating Expense 3005.60
Net Profit 1212.16
Net Profit Margin (%) 27.54
Earnings Per Share (EPS) 73.84
EBITDA 1734.58
Effective Tax Rate (%) 25.13
Particulars MAR 2025 (Values in Cr)
Book Value / Share 555.40
ROE % 7.82
ROCE % 11.67
Total Debt to Total Equity 0.04
EBITDA Margin 26.40
Particulars MAR 2024 (Values in Cr)
Book Value / Share 529.65
ROE % 9.26
ROCE % 13.44
Total Debt to Total Equity 0.02
EBITDA Margin 26.54
Particulars MAR 2023 (Values in Cr)
Book Value / Share 483.23
ROE % 10.33
ROCE % 14.04
Total Debt to Total Equity 0.00
EBITDA Margin 33.35
Particulars MAR 2022 (Values in Cr)
Book Value / Share 435.64
ROE % 18.55
ROCE % 24.84
Total Debt to Total Equity 0.00
EBITDA Margin 39.40
Particulars MAR 2021 (Values in Cr)
Book Value / Share 360.86
ROE % 20.88
ROCE % 27.99
Total Debt to Total Equity 0.00
EBITDA Margin 41.50
Particulars MAR 2025 (Values in Cr)
Book Value / Share 592.08
ROE % 11.62
ROCE % 15.83
Total Debt to Total Equity 0.00
EBITDA Margin 40.27
Particulars MAR 2024 (Values in Cr)
Book Value / Share 546.13
ROE % 12.31
ROCE % 16.65
Total Debt to Total Equity 0.00
EBITDA Margin 37.80
Particulars MAR 2023 (Values in Cr)
Book Value / Share 482.90
ROE % 10.27
ROCE % 13.96
Total Debt to Total Equity 0.00
EBITDA Margin 33.25
Particulars MAR 2022 (Values in Cr)
Book Value / Share 435.68
ROE % 18.56
ROCE % 24.85
Total Debt to Total Equity 0.00
EBITDA Margin 39.42
Particulars MAR 2021 (Values in Cr)
Book Value / Share 360.86
ROE % 20.88
ROCE % 27.99
Total Debt to Total Equity 0.00
EBITDA Margin 41.50
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2556.20
Total Assets 11224.92
Total Liabilities 11224.92
Total Equity 9150.74
Share Outstanding 16
Price to Book Ratio 2.69
Return on Assets (%) 6.22
Return on Capital (%) 7.42
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1839.43
Total Assets 10661.24
Total Liabilities 10661.24
Total Equity 8723.84
Share Outstanding 16
Price to Book Ratio 3.37
Return on Assets (%) 7.24
Return on Capital (%) 8.54
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3770.67
Total Assets 8777.53
Total Liabilities 8777.53
Total Equity 7958.72
Share Outstanding 16
Price to Book Ratio 2.63
Return on Assets (%) 8.89
Return on Capital (%) 9.81
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3093.44
Total Assets 7833.62
Total Liabilities 7833.62
Total Equity 7157.62
Share Outstanding 16
Price to Book Ratio 7.50
Return on Assets (%) 15.46
Return on Capital (%) 16.92
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3005.75
Total Assets 6496.08
Total Liabilities 6496.08
Total Equity 5903.24
Share Outstanding 16
Price to Book Ratio 6.87
Return on Assets (%) 15.34
Return on Capital (%) 16.88
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2432.62
Total Assets 10421.61
Total Liabilities 10421.61
Total Equity 9755.10
Share Outstanding 16
Price to Book Ratio 2.69
Return on Assets (%) 10.45
Return on Capital (%) 11.17
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1598.54
Total Assets 9541.08
Total Liabilities 9541.08
Total Equity 8995.28
Share Outstanding 16
Price to Book Ratio 3.37
Return on Assets (%) 10.93
Return on Capital (%) 11.59
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3766.99
Total Assets 8773.17
Total Liabilities 8773.17
Total Equity 7953.29
Share Outstanding 16
Price to Book Ratio 2.63
Return on Assets (%) 8.84
Return on Capital (%) 9.75
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3085.80
Total Assets 7834.14
Total Liabilities 7834.14
Total Equity 7158.22
Share Outstanding 16
Price to Book Ratio 7.50
Return on Assets (%) 15.47
Return on Capital (%) 16.92
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3005.20
Total Assets 6496.05
Total Liabilities 6496.05
Total Equity 5903.28
Share Outstanding 16
Price to Book Ratio 6.87
Return on Assets (%) 15.34
Return on Capital (%) 16.88
Particulars MAR 2025 (Values in Cr)
Net Income 1062.65
Cash from Operations 1268.53
Cash from Investing 1704.73
Cash from Financing -433.47
Net change in Cash 2185.99
Free Cash Flow 1653.07
Particulars MAR 2024 (Values in Cr)
Net Income 1132.54
Cash from Operations 1302.94
Cash from Investing -1756.91
Cash from Financing -799.41
Net change in Cash -1559.53
Free Cash Flow 1692.87
Particulars MAR 2023 (Values in Cr)
Net Income 1054.58
Cash from Operations 674.83
Cash from Investing 1208.18
Cash from Financing 14.91
Net change in Cash 1587.07
Free Cash Flow 895.76
Particulars MAR 2022 (Values in Cr)
Net Income 1618.55
Cash from Operations 1197.27
Cash from Investing -1002.62
Cash from Financing 34.89
Net change in Cash -176.95
Free Cash Flow 1708.60
Particulars MAR 2021 (Values in Cr)
Net Income 1334.81
Cash from Operations 916.35
Cash from Investing -1524.00
Cash from Financing 1238.46
Net change in Cash 319.38
Free Cash Flow 1145.13
Particulars MAR 2025 (Values in Cr)
Net Income 1465.58
Cash from Operations 1425.84
Cash from Investing 1578.19
Cash from Financing -339.54
Net change in Cash 2312.32
Free Cash Flow 1560.95
Particulars MAR 2024 (Values in Cr)
Net Income 1405.49
Cash from Operations 1452.02
Cash from Investing -2923.92
Cash from Financing -7.39
Net change in Cash -1795.35
Free Cash Flow 1685.61
Particulars MAR 2023 (Values in Cr)
Net Income 1048.40
Cash from Operations 678.78
Cash from Investing 1208.22
Cash from Financing 14.91
Net change in Cash 1591.03
Free Cash Flow 899.70
Particulars MAR 2022 (Values in Cr)
Net Income 1619.04
Cash from Operations 1197.79
Cash from Investing -1010.22
Cash from Financing 34.89
Net change in Cash -184.04
Free Cash Flow 1709.12
Particulars MAR 2021 (Values in Cr)
Net Income 1334.85
Cash from Operations 916.35
Cash from Investing -1524.54
Cash from Financing 1238.46
Net change in Cash 318.84
Free Cash Flow 1145.13
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 34.88 14.41 1.68 267.30 23.12 40.00
BLISS GVS PHARMA LTD. 396.35 32.07 3.51 4192.95 118.35 399.00
CIPLA LTD 1418.20 28.08 3.32 114562.27 1165.55 1672.20
FERMENTA BIOTECH LIMITED 293.20 12.93 2.12 862.92 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 34.88 24.39 4.49 267.30 23.12 40.00
AMRUTANJAN HEALTH CARE LTD. 559.20 25.06 4.36 1616.68 490.00 789.95
ASTRAZENECA PHARMA IND LT 8655.30 104.02 27.08 21638.25 7630.00 10653.05
BLISS GVS PHARMA LTD. 396.35 42.62 3.62 4192.95 118.35 399.00

GLAND PHARMA LIMITED shareholding pattern

Holding
7.51%
51.83%
7.29%
33.35%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

GLAND PHARMA LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
2250.00 -2.72 redarrow
red-green-graph indicator
2 Bearish
14 Bullish
  • 5 Days 2291.30
  • 26 Days 2028.80
  • 10 Days 2209.80
  • 50 Days 1918.80
  • 12 Days 2178.40
  • 100 Days 1847.30
  • 20 Days 2079.60
  • 200 Days 1817.40
2325.63 PIVOT
First Support 2296.57 First Resistance 2342.07 Second Support 2280.13 Second Resistance 2371.13 Third Support 2251.07 Third Resistance 2387.57
RSI 75.21 ADX 50.14 MACD 149.65 Williams % R -14.24 Commodity Channel Index (CCI) 98.58
Date 2026-05-27 Week 392959.00 Same Day 121231.00 Month 262396.00
1 Year 0.76 3 Year 0.66
Over 1 Month
30.27% down
Over 1 Year
51.38% down
Over 3 Months
26.93% down
Over 3 Years
36.39% down
Over 6 Months
30.38% down
Over 5 Years
-6.76% down

GLAND PHARMA LIMITED Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
14 Aug 2025 18.0 Final 14 Aug 2025 Equity shares
16 Aug 2024 20.0 Final 16 Aug 2024 Equity shares
Dividend date Dividend amount Dividend type Record date Instrument type
14 Aug 2025 18.0 Final 14 Aug 2025 Equity shares
16 Aug 2024 20.0 Final 16 Aug 2024 Equity shares

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Gland Pharma Ltd?

Answer Field

Gland Pharma Ltd share price is for NSE ₹ 2,250.00 & for BSE ₹ 2,249.75 as on May 29 2026 03:30 PM.

What is the Market Cap of Gland Pharma Ltd Share?

Answer Field

The market cap of Gland Pharma Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on May 29 2026 03:30 PM.

What is the 52 Week High and Low of Gland Pharma Ltd?

Answer Field

The 52 Week High and Low of Gland Pharma Ltd for NSE is ₹ 2,396.00 and ₹ 1,513.40 and for BSE is ₹ 2,391.25 and ₹ 1,515.00.

What is 1 year return for Gland Pharma Ltd?

Answer Field

The 1 year returns on the stock has been 51.38%.

What is the P/E Ratio of Gland Pharma Ltd Share?

Answer Field

As on May 29 2026 03:30 PM the price-to-earnings (PE) ratio for Gland Pharma Ltd share is 29.33.

What is the PB ratio of Gland Pharma Ltd Share?

Answer Field

As on May 29 2026 03:30 PM, the price-to-book (PB) ratio for Gland Pharma Ltd share is 656.12.

How to Buy Gland Pharma Ltd Share?

Answer Field

You can trade in Gland Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Gland Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Gland Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Gland Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|